Brief Review
The Cardiac Renin-Angiotensin System An Appraisal of Present Experimental and Clinical Evidence Klaus Lindpaintner and Detlev Ganten D uring the past two decades we have witnessed our view of the renin-angiotensin system expand in a major way. Although originally perceived as a classical humoral system in which biologically active molecules are secreted from a dedicated gland to reach their target tissues via the bloodstream, a number of observations have indicated that local renin-angiotensin systems, complete with respect to all the components of the enzymatic pathway, may reside within individual organs or tissues. The existence of these so-called tissue reninangiotensin systems, still conjectural at the beginning of the 1980s, has become much more firmly established during the past decade.1'2 We owe this, in large part, to the advent of molecular biological methods that, for the first time, allowed unequivocal confirmation of local synthesis of the elements comprising the renin-angiotensin system's catalytic cascade in a number of extrarenal tissues. In parallel, observations based primarily on the use of drugs interfering with the renin-angiotensin system have stimulated interest in the pathophysiological importance of local renin-angiotensin systems. This article will examine the evidence for, and the potential physiological and pathophysiological importance of, such a local reninangiotensin system in the heart. The remarkable effectiveness of converting enzyme inhibition in heart failure, which has brought major progress in the therapy of this common and lethal affliction, and the mounting evidence for additional cardioprotective effects of these drugs have sparked particular interest in a cardiac tissue renin-angiotensin system and its role in normal and diseased states.
This year marks the fiftieth anniversary of the first demonstration of a direct interaction between the renin-angiotensin system and the heart3; since then, an impressive body of evidence has been generated to support both existence and functional importance of a local, intracardiac renin-angiotensin system. Over the years, a large number of studies have been directed at various aspects of the interrelation between the heart and the renin-angiotensin system. In the mid-1960s, the first reports about cardiac effects of angiotensin were published; subsequently, a number of investigators dissected out the direct and indirect actions of the peptide on the heart. During the following decade, characterization of secondmessenger pathways laid the basis to our understanding of hormone action, while wide availability of converting enzyme inhibitors promoted rapid accumulation of experimental and clinical experience. Concomitantly, the unique effectiveness of converting enzyme inhibition in patients with heart failure began to be recognized, greatly expanding the therapeutic use of these drugs that formerly had served primarily as antihypertensive agents. The past decade, then, saw the emerging practical application of newly developed molecular biological techniques to the cardiac and other tissue renin-angiotensin systems, rendering conclusive proof of their existence, as mentioned before. In addition, most of our current knowledge of myocardial angiotensin receptors evolved during the late 1980s.
Today, as we stand at the threshold of broadened indications for the use of inhibitors of the reninangiotensin system in a variety of cardiovascular disorders, it seems appropriate to take stock of the knowledge we have gained. In this review, I will attempt to synthesize a comprehensive, integrated view of the cardiac renin-angiotensin system, taking into account biochemical, molecular biological, and functional aspects. Thus, evidence supporting the synthesis and presence of components of the reninangiotensin system in the heart, the regulation of these components independent of the plasma reninangiotensin system, and their integration as a catalytic cascade resulting in the local generation of biologically active peptides will be presented. Furthermore, mechanisms of angiotensin-mediated signal transduction in cardiac tissue, as well as the effects that angiotensin exerts on cardiac function at the cellular and organ level, will be discussed. Last, the possible role which the cardiac renin-angiotensin system may play in pathological states, a role that has become a focus of increasing clinical interest, will be examined. At the outset of this discussion, and as will be elaborated later, the reader is reminded that the term "cardiac renin-angiotensin system" obviously represents an oversimplification: although the emphasis here centers on the cardiac myocyte, a number of other cell types and structures within the heart, in particular the coronary vasculature and the adrenergic nervous system, interact with and may, in fact, contain renin-angiotensin systems of their own.
Elements of the Catalytic Cascade, Their
Regulation, and Integration To differentiate an independently organized and regulated tissue renin-angiotensin system from the circulating plasma system, one must be able to demonstrate local synthesis of the components angiotensinogen, renin, and converting enzyme, which are necessary for generation of the biologically active peptide, angiotensin II. Furthermore, to postulate that the peptide is locally active requires the presence of appropriate receptors and signal transduction systems. In addition, demonstration that the activity of the system or of its individual elements is modulated in response to regulatory stimuli will further confirm the existence of such a system, particularly if regulatory mechanisms can be shown to be independent of the circulating plasma renin-angiotensin system.
Angiotensinogen
A number of investigators have shown that angiotensinogen, a 55 -kDa glycoprotein of the a2-globulin class, is synthesized within the heart. Cardiac angiotensinogen gene expression has been demonstrated in rats4-9 as well as in mice.7 Although gene expression was consistently found in atria4-6,8 and wholeheart homogenates,7,8 its demonstration in ventricles has been somewhat more variable,5'6 10 perhaps owing to the markedly lower concentrations found in ventricles compared with the concentrations found in atria. 68 In addition, interstrain differences in gene expression9 or the use of less sensitive cDNA probes instead of hybridization against cRNA may explain inconsistencies in the findings from several laboratories. In a comparative study, cardiac angiotensinogen mRNA levels were measured as 5% and 1% of those found in the liver of rats and mice, respectively.7 Several groups have studied the regulation of cardiac angiotensinogen expression. Glucocorticoid hormone treatment, a known potent stimulant of hepatic angiotensinogen production, induced marked elevations of angiotensinogen mRNA levels in rat atria4,6 and ventricles.6 This finding is corroborated by the identification of several domains closely related to the putative glucocorticoid and estrogen hormoneresponsive elements in the 5'-flanking region of the angiotensinogen gene."1 Converting enzyme inhibitor treatment was found to suppress angiotensinogen gene expression in the left ventricle,9 whereas dietary angiotensinogen mRNA levels. 12 The finding that nephrectomy, although inducing increased expression in the liver and suppression in aorta, adrenal gland, and lung, did not influence levels of cardiac angiotensinogen mRNA provides further evidence for independent and tissue-specific regulation of cardiac angiotensinogen gene expression.4 Marked increases of ventricular angiotensinogen mRNA levels in pressure overload-induced cardiac hypertrophy"3 as well as in the acutely hypertrophying noninfarcted regions of the heart after myocardial infarction10 have been interpreted as indicating that increased wall stress may represent a trigger for angiotensinogen gene expression. The failure to demonstrate concomitant increases in angiotensinogen message in any other tissue10 adds to the significance of this observation, because it all but dispels the notion that angiotensinogen mRNA measurements in cardiac tissues merely reflect sample contamination by brown adipose tissue (which shows the highest angiotensinogen gene expression among extrahepatic tissues14). Although determination of the precise localization (as to cell type) of angiotensinogen synthesis in the myocardium is still pending, we believe that the available data leave little doubt of its local generation within the heart. Measurement of angiotensinogen protein in cardiac tissue has been problematic because conventional enzymatic assays do not distinguish locally synthesized protein from angiotensinogen sequestrated from the circulating pool. In the liver, angiotensinogen is constitutively secreted into the circulation, and similar processing has been assumed for the intracardially synthesized protein. A study6 examining the kinetics of angiotensinogen release from isolated, perfused hearts has recently provided evidence for active synthesis and secretion of cardiac angiotensinogen. In addition, Western blot analysis disclosed differential migration patterns for cardiac and plasma angiotensinogen (U. Hilgenfeldt, personal communication, 1989), further supporting tissue-specific synthesis in the heart. The presence of multiple mRNA species for angiotensinogen in extrahepatic tissues has been reported"; however, in those that have been characterized, the difference appears to be confined to the polyadenylation site, and therefore, they code for an identical protein. Hence, as with the two plasma forms of angiotensinogen,15 a differential degree of glycosylation, rather than a difference in the amino acid sequence, appears to be the most likely explanation for the observed heterogeneity.
Renin
The aspartyl protease, renin (EC 3.4.23.15), cleaves angiotensinogen to form the decapeptide, angiotensin I, and Des-angiotensin-I angiotensinogen. This represents the first step in the catalytic cascade that leads to the eventual formation of the biologically active peptide, angiotensin II. In the heart, renin gene expression has been documented in sodium restriction has been reported to raise cardiac both mice716-18 and rats7 '19,20; in contrast to angiotensinogen, expression appears to be higher in the ventricles than the atria.19 Levels of renin mRNA in whole-heart homogenates from mice and rats amount to approximately 2% each of mRNA concentrations found in the mouse submaxillary gland and the rat kidney, respectively.7 When signal strengths of angiotensinogen and renin mRNA were compared in the same tissues, angiotensinogen was shown to be far more abundant,7 indicating that renin may be the rate-limiting enzyme governing activity of the system in the heart. Renin protein has been demonstrated in isolated ventricular myocytes using a specific renin antibody,21 suggesting that synthesis occurs in cardiomyocytes as opposed to other cell types. These data confirm a number of older enzymatic and bioassay studies demonstrating renin-like activities in cardiac tissues of several species22-26; the validity of these older studies has previously been questioned (the reninlike activity was attributed to the activity of nonspecific aspartyl proteases). Markedly elevated renin mRNA levels in heart and kidney, but not in testis and submaxillary gland, after sodium depletion indicate the modulatory potential and tissue-specific regulation of intracardiac renin gene expression. 17 The presence of cAMP-responsive elements in the 5'-flanking region of the renin gene emphasizes the potential regulatory interaction with various neurohumoral effector systems. 27 As with renin gene expression, renin enzymatic activity in the heart has been shown to be modulated by a number of interventions. A decrease observed after castration17 points to possible androgen dependence similar to that seen in other tissues.28 Analogous to its effects on renin mRNA expression, sodium starvation also leads to increased enzymatic activity in the heart,'7,24'29 as does exposure to ,8-agonists30 or to the vasodilating agent, hydralazine.12 While renin activity was found to be decreased in isolated myocytes by the calcium antagonist, nifedipine,16 it was found to be increased in whole-heart homogenates after administration of the drug in vivo.31 In contrast, a-methyldopa and angiotensin converting enzyme inhibitors reportedly showed no effect. 12 In the marmoset heart, where local enzymatic activity corresponds to about 0.4% of that found in the kidney, renin activity was specifically inhibited by a primate renin inhibitor in an in vitro system.32 Similarly, inhibition of renin activity by specific anti-renin antibodies was demonstrated in isolated myocytes from rats26 and mice. 30 Although the studies cited above provide strong evidence for local synthesis of renin in the heart, a certain portion of cardiac renin may well be derived from the circulating pool, as indicated by a reported prorenin gradient of 35-58% across the coronary vascular bed.3334 Also, when individual studies are evaluated, it must be kept in mind that because of partial sequence homology and similar molecular weight the distinc-proteases (e.g., cathepsin D) may be difficult without inclusion of appropriate control hybridizations.
Converting Enzyme
The dipeptidyl carboxypeptidase, angiotensin converting enzyme (EC 3.4.15.1, kininase II), catalyzes the final activation step in the formation of angiotensin II as well as the degradation of bradykinin. Most abundant in the lung, the enzyme has been demonstrated in murine,31,35-39 feline,40 bovine,41 and hu-man3841'42 cardiac tissues. Its activity has been reported to be higher in atria than in ventricles.31'37 It has been suggested that cardiac converting enzyme may differ from the enzyme present in other tissues with regard to a number of parameters, such as isoelectric point, monovalent cation requirements,4' and substrate specificity.42 The gene for angiotensin converting enzyme has recently been cloned,43 and tissue-specific, differential transcripts have been demonstrated in endothelium and testis.44 At this writing, no data on the expression or structure of cardiac angiotensin converting enzyme mRNA have been published. The specific location of angiotensin converting enzyme in the heart has not been determined; although an autoradiographic study45 demonstrated selective binding in the endocardium, other investigators46 have shown in functional assays that the presence of angiotensin converting enzyme in the heart is not limited to the endocardial endothelium. Angiotensin converting enzyme activity has been documented in the coronary vasculature47'48; its presence in myocytes, albeit suggested,46 remains to be demonstrated. Little information is available concerning tissue-specific regulation of angiotensin converting enzyme activity in the heart. Its activity in rat ventricles was increased by treatment with calcium antagonists and diuretics,31 and in vitro studies demonstrated increased activity of cardiac, but not of pulmonary, angiotensin converting enzyme after treatment with oxidizing agents.38 Of note, cardiac converting enzyme activity was found increased in pressure-overload-induced hypertrophy49 as well as in ischemic congestive failure.50 Several groups39'51'52 have demonstrated the expected inhibition by converting enzyme inhibitor treatment; differential efficacy of various agents has usually been ascribed to proposed differences in tissue penetration.39'52'53 In addition to angiotensin converting enzyme, alternative pathways leading to the formation of angiotensin II may be active in the heart. Although angiotensin II formation in the rat heart appears to be primarily dependent on converting enzyme, recent studies54'55 indicate that in human and hamster hearts a converting enzyme inhibitor-insensitive, soybean-trypsin inhibitor-sensitive enzyme plays an important role in the conversion of angiotensin I to angiotensin II. Furthermore, kallikrein or kallikreinlike enzymatic activities may lead to the direct activation of angiotion between mRNAs for renin and other aspartic tensinogen to angiotensinll.56
Functional Integration
Having reviewed the evidence for synthesis and presence of the individual elements of the activation pathway of angiotensin II in the mammalian heart, we will now discuss whether these elements interact locally in a physiologically meaningful way to form angiotensin II, the biologically active mediator. Measurements of angiotensin peptides in different regions of the rhesus monkey heart disclosed concentrations that ranged between 100 and 500 pM for angiotensin II and between 30 and 150 pM for angiotensin I. Of note, these concentrations are comparable with physiologically active levels of circulating angiotensin II. Concentrations of both peptides were highest in the right atrium, followed by the right ventricle, left atrium, interventricular septum, and left ventricle. 57 Several approaches have been taken to solve the difficult problem of differentiatin,g peptides sequestered into the myocardium from the circulating pool from those derived from local synthesis. In nephrectomized rabbits, which have undetectable levels of circulating angiotensins (and in which effects of converting enzyme inhibition therefore indicate ongoing local generation of peptides), treatment with a converting enzyme inhibitor lowered atrial angiotensin 11.58 Lack of effect on ventricular angiotensin II concentrations in these experiments was interpreted as pointing to possible tissue-specific differences in regulation, even within the heart. The demonstration of a marked rise in atrial and ventricular contents of angiotensin I after nephrectomy in rats similarly indicates independent function and regulatory potential of the cardiac renin-angiotensin system. 59 In experiments using isolated perfused rat hearts, the presence of cardiac angiotensinogen and its specific cleavage to angiotensin I by renin and to angiotensin II by local converting enzyme were documented and quantified.6'57 Thus, there is convincing evidence in vitro that the cardiac renin-angiotensin system represents a functional and locally integrated system; at this writing, direct biochemical evidence for its activity in vivo has not been presented; because of interference from the plasma renin-angiotensin system, such evidence may be difficult to obtain.
Cardiac Angiotensin Receptors
The final building block necessary to account for all elements of an independent, locally active tissue reninangiotensin system in the heart is the presence of functional angiotensin II receptors. A number of binding studies have demonstrated cardiac angiotensin II binding sites in sarcolemmal vesicle preparations from avian,60 rat,45,61-63 rabbit,64-66 guinea pig,67 bovine,68,69 and human63 myocardium. Most authors find a highand a low-affinity class of binding sites,60,61,64,69 with low and high binding capacities, respectively. It is unlikely that the low-affinity subpopulation represents only an artifact related to tissue freezing and thawing, as was initially suspected70; methodological differences be-tween studies probably explain why in some studies only a single class of binding sites has been identified.65'68 The demonstration in many of the above-cited studies that agonist binding to these sites was specific, saturable, and reversible satisfies the requirements for a hormone receptor. For the high-affinity class of binding sites, KD ranged from 0.65 nM in neonatal rat myocytes61 to 4.5 nM in rabbit left ventricles65; binding capacities were found to vary from 8 (rabbit ventricle membranes64) to 245 (rat myocyte membranes61) fmol/mg protein. In intact neonatal rat myocytes, the receptor density was estimated at 45,000 sites/cell. 61 The low-affinity receptor showed KD values between 5.6 nM in rat myocytes61 and 430 nM in guinea pig ventricles,67 with binding capacities between 220 and 990 fmol/mg protein. 64'69 In most studies, a 10-100-fold difference in affinity and a threefold to 20-fold difference in binding capacity was determined for the two receptor subtypes. In other tissues, highand lowaffinity angiotensin II receptors have been identified as being coupled to activation of the phosphatidylinositol and to inactivation of the adenylate cyclase second messenger pathways, respectively71'72 (see below). It remains to be shown whether the same properties also apply to the cardiac highand low-affinity receptors. Similarly, the high-affinity cardiac angiotensin II receptor has not been examined with regard to the presence of subclasses, as recently demonstrated in other tissues using nonpeptide angiotensin II receptor antagonists and dithiothreitol. 73 In the guinea pig, affinities for both highand low-affinity receptors were higher in the atria than in the ventricles67; in contrast, no such difference was observed in the rabbit. 65 In both species, binding capacities were higher in atria than in ventricles.6567 Autoradiographic data from human hearts show receptors to be localized in the myocardium as well as on coronary vessels and sympathetic nerves,63 emphasizing the major targets of the renin-angiotensin system in the heart; receptor density was found to be similar in the right and left ventricles.
The myocardial angiotensin II receptor molecule has not been isolated or cloned. Recently, the mas oncogene was found to encode a functional angiotensin receptor74 that appears to be coupled to the phosphatidylinositol pathway75 (see below). Its agonist-specificity profile, however, differs from that of the cardiac angiotensin binding sites. Experiments examining the rank order of potency with which angiotensin II analogues compete for binding in cardiac preparations consistently showed highest affinities for angiotensin II, followed by angiotensin III and angiotensin 1.61,63-65,68,69 In contrast, the mas oncogene product is preferentially recognized by angiotensin III,74 which is more typical for angiotensin binding characteristics seen in neuronal tissue. Indeed, although high levels of expression have been found in the brain, little or no mas mRNA has been reported in the heart,76 supporting the notion that the mas oncogene-encoded protein does not represent the myocardial angiotensin receptor. Affinity cross-linking studies on bovine heart membrane preparations have, however, identified a 116,000 molecular weight protein that is protected by nanomolar concentrations of angiotensin II from radiolabeling and to which angiotensin II and analogues bind with the same order of potency as seen in membrane binding studies. 69 Therefore, this protein is likely to represent the high-affinity myocardial angiotensin II receptor. Based on an angiotensin II photoaffinity-labeling study77 in the rat and dog adrenal gland that has identified two macromolecules with molecular weights of 65,000 and 126,000, it has been speculated that the 116,000 molecular weight protein represents a dimer whose subunit aggregation may be initiated or promoted by ligand binding. 60 A number of factors have been found to modulate receptor binding: 1) The effects of ionic milieu on ligand binding vary somewhat in different studies. Binding was generally found to be attenuated in the presence of monovalent cations (Na+, K', Li+, and NH4+)64'69; however, angiotensin II binding was also reported to be stimulated in the presence of Na+.61 Although most authors61,64,65 report increases in binding (sites, not affinity64) in response to divalent cations (Ca2+, Mg2+, and Mn24), one study69 describes attenuated binding in response to exposure in both monovalent and divalent cations. 69 As further elaborated below, guanine nucleotides decrease ligand binding, which has been attributed to a shift from the highto the low-affinity state. 61 2) The effects of developmental regulation on cardiac angiotensin receptors appear to vary between species. Although an increase in receptor number and a progressive shift toward the high-affinity class has been observed during ontogeny of the chick heart in ovo,60 a marked decrease in the number of binding sites occurs in the rat between day 1 and day 10 after birth. 63 This loss of receptor sites may account for the failure to demonstrate binding61 or physiological effects67,78 of angiotensin II commonly encountered in adult rat myocytes and organ preparations (although a few investigators27'79'80 have successfully documented such responses). 3) Angiotensin II tachyphylaxis has been explained by internalization of angiotensin receptors; this may be preceded by peptide-mediated receptor dimerization/aggregation. 60 
Signal Transduction
As indicated above, a number of investiga-tors61,64,65,67 have demonstrated attenuation of ligand binding to myocardial angiotensin II receptors in the presence of guanine nucleotides. Guanine nucleotides are known to accelerate the rate of dissociation of agonist hormone-receptor complexes that are either positively or negatively linked to adenylate cyclase activity. A similar relation is also thought to exist for other G protein-coupled second-messenger systems. Although some studies64'8' examining signal transduction via the adenylate cyclase pathway failed to show modulation by angiotensin II, a recent inves-tigation62 provided evidence for negative coupling of cyclase through an inhibitory (Gi) protein, resulting in a maximal inhibition of 30-40%, with apparent Ki values of 3 and 6 nM in rat and rabbit cardiac sarcolemma. Although the inhibition of cAMP accumulation may be of physiological significance for angiotensin lI-induced cardiac effects (see below), most authors67'81-84 agree that the majority of its actions are mediated via activation of phospholipase C, with subsequent hydrolysis of phosphatidylinositol 4,5-diphosphate and initiation of the catalytic cascade of this second-messenger pathway. Thus, angiotensin II has been found to stimulate phosphatidylinositol turnover,82 evoking sustained elevations of the biologically active compound inositol 1,4,5-trisphosphate83 and its metabolites inositol 4-monophosphate,67'8' inositol 1,4-bisphosphate,8"83 and inositol 1,3,4,5 -tetrakisphosphate83 in guinea pig, rat, rabbit, and chick myocardium. Although diacylglycerol production in response to angiotensin II has not been measured directly in cardiac tissues, both 12-O-tetradecanoylphorbol 13-acetate (TPA), a potent stimulation of protein kinase C, and angiotensin II have been shown to result in selective phosphorylation of an 83-kDa acidic protein in rat cardiomyocytes.84 This protein appears to be identical with the well-characterized protein kinase C substrate.85 Although the similarity of biochemical sequelae seen after angiotensin II and phorbol esters84 indicates that the diacylglycerol branch of the phosphoinositide pathway functions as the biologically important mediator of the effect of angiotensin II on the myocardium, uncoupling of phospholipase C activity from the angiotensin receptor by pertussis toxinmediated ADP-ribosylation of the G protein a-subunit did not compromise the angiotensin Il-stimulated increases in cytosolic free calcium in chick myocytes, as assessed by fura 2 fluorescence.83 Thus, at least in this species, angiotensin II receptormediated stimulation of cytosolic calcium appears to depend on external calcium sources and is not coupled through (pertussis toxin-sensitive) G proteins. Of note, although the effects of angiotensin on phosphoinositol metabolism typically correlate with its physiological effects81"84 (see below), they can apparently also be entirely dissociated from such responses, as has been shown in the guinea pig heart.67 This may provide an alternative explanation for the lack of mechanical response to angiotensin II in the adult rat heart discussed above.
Physiological Effects of Angiotensin in the Heart Our assessment of the physiological effects of the renin-angiotensin system is presently limited mainly to extrapolation of data obtained from exposing myocardial preparations (isolated perfused hearts, atria, papillary muscle strips, or myocytes in culture) to exogenous angiotensin II while carefully excluding effects of other neurohumoral mediator systems. Although an increasing body of evidence very strongly suggests important physiological and pathothe myocardial angiotensin II receptor to adenylate logical roles for the cardiac renin-angiotensin system, a number of caveats should be mentioned regarding this work. To date, no experiments have been reported that were designed rigorously enough to provide unequivocal evidence for direct physiological effects of intracardially synthesized angiotensin. No in vivo data selectively demonstrating the effects of locally generated angiotensin on the heart are available, owing to the complexity of the direct and indirect actions of the renin-angiotensin system on a number of effector systems involved in cardiovascular homeostasis, such as arterial and venous vascular smooth muscle, adrenal cortex, and the central and autonomic nervous systems. Even results obtained while studying isolated organ and tissue preparations may still be confounded by variable and differential effects of the renin-angiotensin system on selective anatomic and cellular components present in such experimental systems. The task before us, then, is to dissect the direct from the indirect effects of angiotensin and to evaluate its action on each of its major targets in the heart: myocytes (on which we will place the emphasis), autonomic nerves, and coronary vessels.
Inotropic Effects
After the early reports of positive inotropic effects of angiotensin,86'87 investigative efforts focused on the separation of direct and indirect actions of angiotensin II, the latter being primarily due to its modulation of sympathetic nervous function, as we now know. Investigators used pharmacological agents, such as 18-blockers60'87-89 and reserpine,87'90-92 extrinsic cardiac denervation,66'93 or isolated cardiomyocyte preparations79,81,84 to verify direct inotropic or chronotropic effects of angiotensin. Additional maneuvers, such as demonstrating additive effects of maximal adrenergic stimulation and angiotensin ll,60 and lack of influence of agents such as atropine, phentolamine, or indomethacin89 on the angiotensin-mediated effects further supported the concept of direct myocardial actions of the peptide. In contrast, the angiotensin receptor antagonist saralasin specifically inhibited cardiac responses to angiotensin.61'88'94 When sympathetic facilitation was thus carefully avoided or excluded, dose-dependent direct positive inotropic effects of angiotensin II have been shown in isolated cardiac preparations (atria and papillary muscle strips) from rabbits,94 96 concentration that is in good agreement with the KD values for the highaffinity receptor determined in studies already discussed. In isolated, perfused hearts of cardiomyopathic and normal hamsters, a similar positive inotropic effect has been demonstrated, albeit at considerably higher than physiological concentrations of angiotensin in the perfusate (around 10-6 M).s5 In the inotropic response has ranged from very small88 to equipotent with the maximal response to sympathetic nerve stimulation96 and on up to a 15-fold increase in developed tension on exposure to pharmacological doses. 95 There is now general agreement that the inotropic and chronotropic effects of angiotensin on the cardiomyocyte are partly or exclusively mediated by its effect on calcium homeostasis and transmembranous calcium conductance. This was first suggested by studies89'92 that documented a change in the contour of phase 2 (the plateau phase) of the cardiac action potential. The plateau phase is known to be maintained by the summation of a number of small ionic currents, one of which, the so-called "slow inward current," is carried principally by calcium ions and has been closely linked to the contractile properties of cardiac muscle. These slow channels are blocked by certain divalent cations, such as Mn2+, Co2+, Cd2+, Ni2+, and La2+ as well as by verapamil and similar agents. When "fast" sodium channels are blocked with tetrodotoxin or inactivated by partial depolarization, as achieved with moderate elevations in extracellular K+ concentration, electrical and mechanical responses are rendered primarily calcium dependent. Spontaneous electrical activity and responses to electrical stimulation, abolished under these conditions, were restored by the application of nanomolar concentrations of angiotensin 11,94 strongly indicating enhancement of the slow inward current as its mechanism of action. Reversal of this effect by the addition of either Mn24 or verapamil lent further support to this concept, as did experiments in isolated cardiac Purkinje fibers.'00 There, angiotensin II increased height and duration of the plateau phase of the action potential and, in voltageclamped cells, promoted a substantial inward shift in membrane current. These changes were accompanied by concomitant increases in peak developed tension, establishing their functional and physiological importance. Both electrical and mechanical effects were reduced when external calcium concentrations were decreased and were inhibited by calcium channel antagonists, which further supported their mediation via the slow inward current. Isolated neonatal rat cardiomyocytes have recently been used to establish the link between angiotensin's effects on the slow inward current and its recognized modulation of the phosphatidylinositol pathway, as well as to characterize the channel involved as the L-type cadmiumsensitive calcium channel.81'84"10' Thus, both the phorbol ester TPA and angiotensin II, through activation of protein kinase C, resulted in identical increases of steady-state as well as transient components of the calcium current. These electrical events were paralleled by mechanical response (in this model, an increase in spontaneous beating frequency).81,84 Similarly, angiotensin Il-induced enhancements in cardiac fiber shortening velocity and sarhands of different investigators, the magnitude of the comere shortening are sensitive to staurosporin, an inhibitor of protein kinase C.102 The angiotensinstimulated increases in calcium conductance may result from recruitment of previously inactive channels (i.e., increases in single-channel conductance) and/or alterations in channel kinetics.103 It has been suggested that the observed inhibitory action of angiotensin II on adenylate cyclase in the myocardium may result in retardation of cAMP-mediated calcium uptake by intracellular organelles and thus potentate the effects of calcium influx and release from subcellular structures. 60, 62 In addition to enhancing transmembranous calcium fluxes, a recent study104 using patch-clamped neonatal rat myocytes demonstrated that angiotensin II also influences voltage-dependent sodium channels, most likely also via the activation of protein kinase C. Thus, increases in the frequency of opening and in the rates of activation and inactivation of single-channel sodium currents were observed after outside application of angiotensin II, mimicked by TPA, and abolished by pretreatment with TPA. This finding may be of relevance with regard to the proposed arrhythmogenic actions of angiotensin II (see below).
The documented mediation through slow channels is in agreement with previously noted features of angiotensin's effect on contractile function, showing increases in the rate of tension development and maximum developed tension but no shortening of time to peak tension.89 91 Other previously noted characteristics of angiotensin-mediated effects on the myocardium include their delayed onset after bolus administration40 and their prolonged duration.40,66'92 Several authors have commented on the unusually late occurring tachyphylaxis to angiotensin 11.40,66 Interestingly, its positive inotropism appears to make lesser demands on myocardial oxygen supply than that of catecholamines or cardiac glycosides.93 A possible improvement of diastolic relaxation characteristics after angiotensin II is conjectural.79'81'84'87'89
There have been isolated reports81'84"105-107 describing a negative inotropic effect of angiotensin II. In most of these studies, this was probably due to limiting effects of angiotensin-provoked coronary vasoconstriction on contractile performance. Angiotensin II increases coronary resistance both by direct action on vascular smooth muscle and by sympathetic facilitation,108'109 thus interfering with the evaluation of inotropic effects in studies in intact animals90 as well as in isolated heart preparations.80'96'98 These confounding effects can be avoided by substituting the wild-type [Pro7] with Ala, which effectively rids the peptide of activity on vascular smooth muscle and renders it highly cardioselective,110 confirming its positive inotropic actions. The negative inotropic effect of angiotensin II observed in neonatal rat ventriculocytes,81'84 which was independent of the positive chronotropic effect observed in the same experiments, has so far remained without explanation; it has been speculated that it may result from decreases in resting calcium levels, in the magnitude of the calcium transient, or in the sensitivity of myofilaments for calcium, all effects that would appear to be unique to this preparation. Indeed, a recently reported study,102 using an apparently comparable experimental setup, documented increases in fractional sarcomere shortening and maximum shortening velocity in isolated cardiomyocytes on exposure to angiotensin. As has been discussed, the lack of an inotropic effect in guinea pig and adult rat myocytes is thought to be related to uncoupling of angiotensin receptors in these species.67'78 Thus, there is little evidence for a negative effect of angiotensin II in normal myocardium; however, several recent reports indicate that the situation may be different in pathological states: ischemic systolic and diastolic ventricular dysfunction was exaggerated after angiotensin infusion,"' and diastolic dysfunction in pressureoverload hypertrophy was improved by converting enzyme inhibition,"12 while angiotensin II caused further deterioration.1"3 A possible direct cardiac action of angiotensin I has been reported by several authors4092,99114"'5 but appears unlikely to represent a specific effect and remains conjectural. Conversion to angiotensin II within the experimental preparation by converting enzyme or an alternative enzymatic pathway54 is the most likely observation, since angiotensin I-saturated binding sites could not be demonstrated and the effect wasat least in one set of experiments -abolished by the concomitant administration of captopril.1"6
Chronotropic Effects
In contrast to the well-documented direct inotropic influences of angiotensin II, reports concerning its chronotropic effects have been somewhat less consistent. In isolated atria from cats, no chronotropic response was observed,87 whereas preparations from dogs,88 rabbits,1"7 and guinea pigs99 showed variable increases in heart rate after angiotensin II. In some of these studies this may have been due to insufficient exclusion of sympathetic facilitation.99"1'8 However, studies in cultured neonatal rat heart cells6181'84 provide evidence for a direct positive chronotropic effect, which is blocked by specific angiotensin antagonists. Also, the demonstrated high density of angiotensin binding sites within the sinoatrial and atrioventricular nodes has been viewed as consistent with the concept that angiotensin might affect heart rate by direct action on the specialized conduction system.45 In the intact animal, angiotensin may influence heart rate through a multiplicity of mechanisms,1"8 such as release of catecholamines from the adrenal medul-la1"9 or facilitation of sympathetic neurotransmission in cardiac adrenergic nerve terminals109"120 and sympathetic ganglia.12' In addition, a centrally mediated inhibitory action of angiotensin on cardiac vagal afferents has been reported,122 corresponding, perhaps, with the lack of reflex tachycardia observed in patients treated with converting enzyme inhibitor.123"24 Finally, a possible direct tachycardic re-sponse to systemic angiotensin in vivo is of course normally blunted by baroreceptor modulation."18
Growth-Promoting Effects
Recent work125 has demonstrated the intriguing possibility that angiotensin, in addition to its inotropic and chronotropic actions, may exert a major influence by acting as a growth factor. Although the efficacy of converting enzyme inhibitors, in contrast to other vasodilators,126 in preventing or reversing hypertensive cardiac hypertrophy has long been recognized in experimental animals127'128 and humans,129,'30 it could never be dissociated from concomitant systemic hemodynamic effects afforded by these agents. Similarly, only administration of pressor, but not of subpressor, doses of angiotensin13' has successfully induced cardiac hypertrophy. Two recent studies, however, showed that treatment with small doses of converting enzyme inhibitors that did not affect blood pressure132 or afterload13 resulted in prevention and regression of cardiac hypertrophy in aortic bands rats, suggesting an effect of angiotensin II on the development of cardiac hypertrophy that is independent of systemic hemodynamics. This notion is supported by earlier studies measuring incorporation of radiolabeled thymidine, uridine, or isoleucine into isolated rat atria and ventricles, which demonstrated that angiotensin increases DNA turnover,133 RNA turnover133 and content,134 and protein synthesis'33-35 within as little as 2-3 hours of incubation. 133 A direct effect of angiotensin on the nucleus, including stimulation of transcription, has been proposed, based on findings of preferential localization of radiolabeled angiotensin II in the nuclear zone (and mitochondria) of cardiac muscle,136 of an interaction between angiotensin and specific highaffinity chromatin acceptors,137 and of a permissive effect of angiotensin II on chromatin solubilization.138 An "intracrine" cardiac renin-angiotensin system has been postulated based on the possibility that such nuclear interaction would involve angiotensin synthesized and activated within the same cell.21 An alternative, or perhaps associated, mechanism for the trophic effects of angiotensin is suggested by the recent findings139-'4' that the peptide, via activation of protein kinase C and modulation of cytosolic calcium, activates the nuclear proto-oncogene c-fos. The c-fos protein, in turn, has been shown to play an important role in the regulation of cell proliferation and protein synthesis in cardiac muscle. 142 Similarly, expression of the early growth response gene 1, Egr-1,143 another TPA-sensitive factor associated with cell growth and proliferation, has been shown to be induced by angiotensin II in isolated rabbit cardiomyocytes. 144 The observation that in guinea pigs angiotensin activates second messenger pathways but fails to elicit any contractile response67 has invited speculation that stimulation of protein synthesis and other proliferative mechanisms may be the predom-There are several lines of evidence supporting a role of the intrinsic cardiac renin-angiotensin system in regulation of cardiac growth; most of them, however, are indirect, and so far none provides conclusive proof. Spontaneously hypertensive rats, which develop marked cardiac hypertrophy, show increased expression of both the renin145 and the angiotensin-ogen9 genes in the heart when compared with Wistar-Kyoto rats, the normotensive controls. However, detailed studies correlating mRNA levels with the developmental stage of cardiac hypertrophy and excluding a mere strain difference have not yet been performed. A structural difference of the renin gene, which has been found to distinguish the spontaneously hypertensive and normotensive rat strains,146'147 may be of physiological relevance, although a simple correlation with blood pressure or cardiac mass could not be demonstrated.147 Increased cardiac converting enzyme activity49 and angiotensinogen gene expres-sion13 in the hypertrophic left ventricles of aortic banded rats and a rise in angiotensinogen gene expression10 and converting enzyme activity50 in the hypertrophying,148,149 noninfarcted portion of the left ventricle after coronary occlusion stress the potential role of the cardiac renin-angiotensin system in the pathogenesis of cardiac hypertrophy.
Interaction With Other Neurohumoral Systems
There is general consensus in the literature that facilitation of sympathetic nervous influences on the heart by angiotensin II contributes importantly to its inotropic and chronotropic actions. It is very likely that adrenergic cardiac nerves are one of the main targets of an activated intracardiac renin-angiotensin system in vivo as well as in vitro. The majority of studies conclude that this facilitation is based primarily on an increase in the amount of neurotransmitter released from presynaptic nerve terminals. 95,96"109,150-152 The exact mechanism of signal transduction by which angiotensin produces this effect in neuronal tissue is not well understood but appears to differ from that observed in myocytes,6781,84 in that the diacylglycerol/ protein kinase C arm of the phosphatidylinositol hydrolysis pathway seems not to be involved.153 In addition, coupling between prejunctional receptors and phospholipase C is not afforded by pertussis toxinsensitive GTP-binding proteins. Other mechanisms of sympathetic facilitation by angiotensin that have been demonstrated include attenuation of prejunctional reuptake,109"154 stimulation of sympathetic ganglia,121,155 increased catecholamine biosynthesis,156,'57 release of catecholamines from the adrenal medulla,158 and sensitization of postjunctional structures.159,160 Recent autoradiographic data localizing angiotensin receptors on cardiac adrenergic nerves63 emphasize the potential role that modulation of local sympathetic outflow may play in the overall physiological effects of the cardiac renin-angiotensin system. Such a role is further supported by the markedly attenuated effects on heart rate, coronary flow, and contractility observed after inant cardiac action of the peptide in this species. addition of converting enzyme inhibitor to the perfus-ate of isolated perfused hearts stimulated via preserved sympathetic cardiac nerves.120,16' Also, converting enzyme inhibitors greatly decreased norepinephrine overflow from isolated perfused hearts subjected to coronary artery occlusion. 162 The sympathetic facilitation by angiotensin II and its inhibition after converting enzyme inhibitor application that these studies demonstrated in isolated Langendorff hearts clearly support the concept of local synthesis of cardiac angiotensin. Although an effect, so far unrecognized, of bradykinin potentiation on adrenergic function cannot be excluded, these experiments provide rather compelling evidence for a physiologically functional interaction between locally synthesized angiotensin II (i.e., the cardiac renin-angiotensin system) and the sympathetic nervous system in the heart.
In addition to its direct myocardial action and its effects of sympathetic facilitation, angiotensin affects other neurohumoral effector systems. The impact of this interaction, at least in the heart, is still poorly understood and will therefore be only briefly addressed. Angiotensin-induced generation of prostaglandins in the heart163 is probably mediated via phospholipase C (and possibly phospholipase A2) activation, release of arachidonic acid from membrane phospholipids, and its subsequent conversion to endoperoxides via the prostaglandin synthesis pathways.60 Physiological cardiac responses to prostaglandins include coronary vasodilation,164165 which is probably related to direct effects on the vascular smooth muscle as well as to the reported inhibitory effects of prostanoids on prejunctional norepinephrine release166 and on vascular responsiveness to catecholamines.167 In addition, prostaglandins stimulate adenylate cyclase,60 which may explain their reported chronotropic'68 and inotro-picl69 actions. Since converting enzyme inhibition is the predominant pharmacological maneuver used by many investigators to interrogate the role of angiotensin II in the heart, direct cardiac effects of bradykinin, which is potentiated by these drugs, must be considered. Bradykinin has been shown to have positive inotropic98,152,170 and chronotropic17' effects, to increase coronary flow,87 and also to raise local concentrations of prostaglandins in a variety of tissues including the heart.172
Potential Clinical Relevance of the Cardiac
Renin-Angiotensin System As discussed above, to date no direct evidence has been presented that links the activity of the cardiac renin-angiotensin system to the regulation of cardiac function under normal physiological conditions. However, recent observations based on the clinical use of converting enzyme inhibitors have raised speculations about the possible role of the cardiac renin-angiotensin system in several pathological states. Among them are chronic congestive heart failure, acute myocardial ischemia, and post-Chronic Congestive Heart Failure Although most vasodilators improve symptoms of congestive heart failure, converting enzyme inhibitors have emerged as being more effective and are associated with fewer side effects than other agents.173 Importantly, converting enzyme inhibitors represent the only class of pharmacological agents that has been shown to reduce mortality in patients with heart failure.173,174 This discrepancy between converting enzyme inhibitors and other vasodilators, which has also been documented in experimental animals,175,176 is difficult to reconcile with the apparently similar mechanism by which all vasodilators benefit the failing heart, namely by reducing preload and afterload. Additional effects, among them inhibition of the cardiac renin-angiotensin system, have been implicated.12'57 The reasons for the superiority of converting enzyme inhibitors with regard to improvement of functional capacity and longevity are unclear. Modulation of angiotensin's influence on myocardial metabolism (see below) may play a role in this beneficial effect of converting enzyme inhibition by improving myocardial energy balance. Alternatively, converting enzyme inhibitors may interfere with direct effects of angiotensin on myocardial protein composition, as suggested by the postulated effects of angiotensin on transcriptional control10"42 (see above) and by the observation that converting enzyme inhibitors induced normalization of a pathologically shifted myosin isoenzyme profile.'77 Also, there is evidence that the pathologically altered left ventricle no longer shows a positive inotropic response to angiotensin but responds instead with a further decline in both systolic and diastolic function.1'11-3 In addition, the attenuation of ventricular dysrhythmias observed in heart failure patients treated with converting enzyme inhibitors'78-181 may play a role in their improved survival. Acute Myocardial Infarction Growing evidence points to a "cardioprotective" effect of converting enzyme inhibitors in the acutely ischemic or infarcting myocardium182; since many of the data suggesting such an effect are derived from studies in isolated hearts, a role for the intrinsic cardiac renin-angiotensin system is suggested. Coronary vasodilator action of converting enzyme inhibitors due to interference with kininase II183 or due to a sulfhydryl group-mediated effect184 or complex changes in systemic hemodynamics that reduce myocardial oxygen demand and raise anginal threshold185 may account in part, but probably not exclusively, for this cardioprotection. While infarct size after coronary artery ligation was reduced in dogs treated with converting enzyme inhibitor,'86 both area at risk and infarcted area were smaller than would have been predicted from the concomitant augmentation of coronary flow afforded by the drug. This pointed to additional effects of the converting enzyme inhibitor, possibly involving myocardial metabolism. Indeed, infarction adaptive processes. isolated perfused hearts subjected to transient isch-emia demonstrated preservation of ventricular creatine phosphate, adenosine triphosphate, and glycogen stores when a converting enzyme inhibitor had been added to the perfusate,183 whereas creatine phosphokinase, lactate dehydrogenase, lactate, and purine183'87 overflow were markedly reduced. These findings were accompanied by improved parameters of ventricular function and enhanced coronary flow. 183 Although the cardioprotective effect was abolished by the addition of angiotensin II to the system,183 it appears to be mediated at least in part by converting enzyme inhibitor-mediated bradykinin potentiation. Addition of bradykinin to the perfusate resulted in improvements of mechanical and metabolic parameters indistinguishable from those afforded by converting enzyme inhibition, whereas converting enzyme inhibitor-mediated effects were abolished by concomitant infusion of a specific bradykinin antagonist. 188 The effects of bradykinin, in turn, may involve argumentation of local prostanoid production,189 since indomethacin has also been found to negate converting enzyme inhibitor-mediated cardioprotection.162
Reperfusion Arrhythmias
Along with their beneficial effects on myocardial metabolism, converting enzyme inhibitors were found to have a remarkable effect on reperfusion arrhythmias. Several investigators, 162, 183, 187, 188, 190, 191 using a variety of converting enzyme inhibitors, have demonstrated a significant reduction of both incidence and mean duration of malignant arrhythmias in different models. Again, the effects of converting enzyme inhibitors were abolished by simultaneous administration of angiotensin II, but not of angiotensin 1,183 and by exposure to a bradykinin inhibitor.188 Bradykinin duplicated the antiarrhythmic effects of converting enzyme inhibition,188 indicating complex effects of several neurohumoral mediator systems. Moreover, dramatic reductions in norepinephrine overflow from ischemic hearts after converting enzyme inhibitor treatment imply that the antiarrhythmic effect may in part result from attenuation of angiotensin ll-related sympathetic facilitation162 and may thus not necessarily be related to limitation of ischemic myocardial damage in the acute setting. Indeed, electrophysiological studies in, thus far, untreated animals 7 days after myocardial infarction demonstrated complete prevention of inducible ventricular tachycardia after acute administration of converting enzyme inhibitors,192 whereas infusion of angiotensin II rendered previously noninducible animals susceptible to stimulus-induced ventricular tachycardia.193 A significant decrease in the duration of ventricular refractoriness shown in healthy, noninfarcted hearts in response to angiotensin II193 may be related to the increased inducibility of malignant ventricular tachyarrhythmias seen after infarction. Thus, a role for converting enzyme inhibitors as antiarrhythmics, particularly in ischemia and congestive heart failure, has been proclaimed,194 invoking also converting enzyme inhibitor-mediated modulation of other proarrhythmic factors such as left ventricular dysfunction and hypokalemia as possible mechanisms. Several authors178-181 have observed a reduction of ventricular ectopy in converting enzyme inhibitortreated patients suffering from heart failure, which would seem to corroborate this hypothesis; however, no controlled clinical studies have been reported so far.
Stunned Myocardium
A further potentially important clinical aspect of converting enzyme inhibitors in acute ischemia relates to their recently reported beneficial effects on the "stunned" myocardium. 195 This term has been coined to describe the transient contractile dysfunction that occurs as a postischemic phenomenon in the absence of actual myocyte damage or death, commonly found in the peri-infarction area. As has recently been shown by scanning electron microscopy,196 the morphological substrate of the stunned myocardium appears to be a major disruption of the extracellular collagen matrix interconnecting cardiac myocytes, which themselves appear perfectly preserved. It has been proposed that collagenases, normally present in the myocardium'97 and activated by oxygen-derived free radicals198 produced during reperfusion,199200 may account for this damage. Since the extracellular matrix is of major importance for the mechanical transduction of contractile force, as well as for resting tension and diastolic recoil, overall functional impairment will result. Converting enzyme inhibitors have been found to significantly attenuate this dysfunction after transient ischemia. 201, 202 It is unlikely that their effects are simply the result of decreased afterload, since other vasodilators failed to show similar effects. 202 Rather, a direct effect on preserving the integrity of the intercellular collagen matrix, perhaps via the free radical scavenging properties of sulfhydryl group-containing converting enzyme inhibitors,201 combined with a decrease in systolic distension may be involved, resulting in attenuation or prevention of myocyte "slippage."'49'203
Ventricular Remodeling
The term "ventricular remodeling" describes a series of pathological changes that take place after myocardial infarction and that set the stage for the progressive ventricular dilation and ultimate pump failure commonly seen in the late stages of ischemic heart disease. Of note, ventricular enlargement is not only a sequela of distension of the scar (infarct expansion) but also of a restructuring process affecting the remaining noninfarcted myocardium. 148, 204, 205 Importantly, this dilation is not necessarily associated with increased filling pressures and is characterized by a rightward shift of the ventricular pressure-volume curve typical for volume overload hypertrophy. 206, 207 Histologically, early occurrence of myocyte hypertrophy148 has been observed; associated side-to-side slippage of myocytes leads to increased ventricular volumes while wall thickness of the noninfarcted myocardium is maintained or even reduced. 149, 203 The resulting increase in wall stress fosters, over time, the development of decompensated, eccentric ventricular hypertrophy. This process also involves progressive myocardial fibrosis with rearrangement of the architecture of the extracellular matrix.208'209 Thus, ventricular remodeling resembles, with regard to collagen distortion and myocyte slippage, the situation of the stunned myocardium, albeit with more permanent structural sequelae. The deleterious consequences of ventricular remodeling raised the question whether interference with this process might be beneficial. Indeed, prevention or attenuation of ventricular remodeling after myocardial infarction by the administration of converting enzyme inhibitors has since been shown to be a highly effective means of improving functional status and decreasing mortality in both experimental animals and humans. 175, 176, 210, 211 The observation that converting enzyme inhibitors, but not other vasodilators,212 seem to be effective in preventing or reversing the process of myocardial remodeling suggests that mechanisms in addition to reduction in afterload may be at play. Although it has been reasoned that the effects of converting enzyme inhibitors on preload may account for their superior utility,211 their effect on the cardiac tissue renin-angiotensin system represents an alternative explanation. The recent demonstration of enhanced cardiac angiotensinogen gene expression in the noninfarcted myocardium during the early period of ventricular remodeling10 strongly favors a role of the cardiac renin-angiotensin system in this process. Angiotensin may affect ventricular remodeling through its proposed growth factor properties addressed earlier, [133] [134] [135] [139] [140] [141] thus promoting myocyte hypertrophy; in addition, angiotensin may also directly affect collagen and connective tissue architecture. The finding that chronic infusion of subpressor doses of angiotensin II induces a marked fibrotic response in the rat heart213 reminiscent of the changes seen in postinfarction remodeling may be related to increases in myocyte membrane permeability and subsequent fibroblast proliferationl25,213 seen after exposure to the peptide. Similarly, focal myocardial necrosis and coronary vasculitis induced by angiotensin II214-216 were felt to be the result of a direct effect on the heart rather than of a rise in blood pressure. 217 
Additional Observations
The demonstration of several of the cardioprotective effects of converting enzyme inhibitors in isolated heart preparations suggests that the cardiac renin-angiotensin system may be stimulated in myocardial ischemia and, therefore, may act as a significant contributing factor in ischemic damage and associated complications. If so, what is the evidence that the cardiac renin-angiotensin system is activated in the setting of myocardial ischemia? Hypoxia has been shown to activate the circulating renin-angiotensin system218; its effects on tissue renin-angiotensin systems are not known. A shift from the classical two-step activation cascade to the direct cleavage of angiotensin II from angiotensinogen by kallikrein or a kallikreinlike proteinase has been reported to occur under conditions of myocardial ischemia and resultant tissue acidosis.56 Furthermore, cardiac, but not pulmonary, converting enzyme activity has been reported to be markedly stimulated by exposure to oxidizing agents.38 Although these data were obtained in vitro, a potentiation of converting enzyme activity in a reperfusion-induced free radical environment might be hypothesized based on these findings. As yet, however, there is no direct and reliable evidence for an activation of the cardiac reninangiotensin system in ischemia.
As a final consideration with regard to the effects of converting enzyme inhibitors in ischemic heart disease, we shall briefly address the following controversy: are these effects related to inhibition of angiotensin converting enzyme or to the presence of a free radicalscavenging sulfhydryl group in the molecule? Although there is no consensus as to whether free radicals contribute to myocardial injury, their role in the stunned myocardium seems relatively certain.219 It has been established that those agents that contain a sulfhydryl group (captopril and zofenopril) do in fact possess free radical-scavenging properties,201 whereas others do not. In many experiments by different investigators,162,201,202 captopril has consistently been found effective as a cardioprotective agent in both stunned myocardium and injury, while enalapril's effects were somewhat more variable. This has been interpreted as supporting the notion that the presence of a sulfhydryl group, rather than inhibition of converting enzyme, represents the responsible mechanism. However, use of the prodrug instead of the active moiety in in vitro experiments by some investigators may also account for these findings. 202 In addition, ramipril, a nonsulfhydryl converting enzyme inhibitor has been highly effective as an experimental cardioprotective agents.132183188 Although the potential role of free radical scavenging in stunned myocardium shall not be disputed, it is certainly not the exclusive mechanism by which converting enzyme inhibitors are effective, as exemplified by the successful use of enalapril in this setting.201 Thus, the explanation for the somewhat greater efficacy of captopril lies most likely in the fact that the two sulfhydryl group-containing drugs (captopril and zofenopril, along with fosinopril) happen to be specifically distributed to the myocardium and therefore show markedly higher activity against cardiac converting enzyme than any of the other agents.53
Conclusion and Outlook The work reviewed in these pages represents an impressive effort by a worldwide scientific community to solve the riddles that the renin-angiotensin system still holds for us. It is reassuring that despite great technical difficulties human curiosity prevails and that out of many small contributions eventually a larger picture emerges. Although some continue to discount the role of the cardiac renin-angiotensin system in circulatory control,220 we think that the data presented above provide rather conclusive evidence that a cardiac tissue renin-angiotensin system exists, that it produces biologically active peptides via locally functional catalytic pathways, and that it shows physiological effects. In addition to its direct modulatory influence on cardiac contractility, angiotensin's effects on sympathetic neurotransmission, on myocardial metabolism, and on cellular growth, which we have just begun to explore, may be among the most interesting aspects of the cardiac reninangiotensin system. The expansion of our understanding of this system and the concomitant advances in the treatment of heart disease represent an impressive example of how basic research and clinical practice can interface to meet their common goalimproving the human condition. Still, as has been pointed out, much work remains to be done to further characterize the cardiac renin-angiotensin system and to be able to exploit fully the therapeutic advantages that its modulation may offer. 
